Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, shares some insights into mechanisms of resistance to CAR-T cell therapy in patients with lymphoma. Dr Ruella highlights three major causes of resistance, including T-cell dysfunction, the role of the tumor microenvironment, and tumor intrinsic mechanisms, and concludes by discussing novel strategies being explored to overcome these. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть